The COVID-19 pandemic has placed enormous stress on both healthcare systems and researchers, and people all across the sector are looking for digital solutions to help ease the pressure.
From AI-driven vaccine candidate selection to the mass roll-out of virtual consultations, digital transformation is accelerating at an unprecedented rate in the face of COVID-19.
Artificial intelligence (AI) has now moved beyond its initial hype towards becoming a key part of the pharma industry – with many companies looking to partner with AI drug discovery start-u
The use of artificial intelligence (AI) in drug development has been hyped up for some time now – and the COVID-19 pandemic is finally a chance for these technologies to prove their worth.
So, what is this thing we call ‘empathetic technology’? While the two terms seem like antonyms, the intersection is proving to be a rich opportunity for innovation.